Brand name: Brineura TM
Active ingredients: cerliponase alfa
What it is used for
Brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
How to take it
This medicine is a pack that contains more than one part.
Part 1: Injection, solution
Clear to slightly opalescent and colourless to pale yellow solution, that may occasionally contain thin translucent fibres or opaque particles.
The way to take this medicine is: Intracerebroventricular.
Part 2: Injection, solution
Clear, colourless liquid, essentially particle free
The way to take this medicine is: Intracerebroventricular.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Storage instructions
- Store at minus 20 plus or minus 5 degrees Celsius (deep freeze)
- Protect from Light
- Store in Original Container
- Store Upright
- Shelf lifetime is 2 Years.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient cerliponase alfa
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme